FBR Capital Markets & Co.’s Senior Equity Research Healthcare Analyst Madhu Kumar, Ph.D. Named to Institutional Investor’s 2017 All-America Research Team Rising Stars List

At B. Riley and Co., we offer unparalleled value, proprietary research, and creative banking solutions to our clients.

FBR Capital Markets & Co.’s Senior Equity Research Healthcare Analyst Madhu Kumar, Ph.D. Named to Institutional Investor’s 2017 All-America Research Team Rising Stars List

FBR Capital Markets & Co.’s Senior Equity Research Healthcare Analyst Madhu Kumar, Ph.D. Named to Institutional Investor’s 2017 All-America Research Team Rising Stars List

FBR Capital Markets & Co.’s Senior Equity Research Healthcare Analyst Madhu Kumar, Ph.D. Named to Institutional Investor’s 2017 All-America Research Team Rising Stars List

FBR Capital Markets & Co., LLC (“FBR”), a leading full service investment bank and wholly-owned subsidiary of B. Riley Financial, Inc. (NASDAQ:RILY), is proud to announce that its Senior Equity Research Analyst Madhu Kumar, Ph.D. was named to Institutional Investor’s 2017 All-America Research Team Rising Stars list in the Biotechnology/mid- and small-cap category.

Dr. Kumar recently joined FBR’s Healthcare Research Group in New York as Senior Research Analyst and Senior Vice President covering therapeutics and biopharmaceuticals.

“I’m honored to be named as one of Institutional Investor’s 2017 All-America Research Team Rising Stars and sincerely appreciate the recognition,” said Kumar. “Having recently joined FBR’s Research group, I look forward to contributing to the expansion of the firm’s healthcare sector expertise and service offerings.”

“On behalf of the firm, I want to congratulate Madhu on this latest recognition,” said Bryant Riley, Chairman and CEO of B. Riley Financial. “We’re continuing to expand our industry expertise and building out our healthcare team with leaders like Madhu is a perfect example of our commitment.”

Prior to FBR, Dr. Kumar worked at Chardan Capital Markets, LLC with a focus in disruptive technologies in verticals including small RNA therapies, RNA therapies, and complement therapies. Previously, he was a scientific advisor at Wilson Soncini Goodrich & Rosati, where he drafted both national and international patent applications related to various technologies in the healthcare sector. Dr. Kumar graduated with a B.A. in Biochemistry and Chemistry summa cum laude at the University of Pennsylvania, and received his Ph.D. in Biology at the Massachusetts Institute of Technology where he notably developed a lentiviral vector for co-delivery of small RNAs and gene modification technologies.

Quick Nav
Quick Nav
Research